Adjuvant Radiotherapy After Preoperative Chemotherapy

  • Makbule Tambas
  • Kamuran Arslan Ibis
  • Merdan Fayda


The decision to treat patients with radiotherapy after preoperative chemotherapy is still largely based on the initial clinical staging of the patients. The use of three-field radiotherapy (RT) including the chest wall/breast and regional lymphatics after surgery in locally advanced, node-positive patients receiving neoadjuvant systemic chemotherapy is well established. Patients with clinically staged T3–T4 tumors, pathological non-complete responders in the axilla, and younger patients (<35) with cT2N1 or worse disease should be treated with RT according to retrospective data. A pooled analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B18 and B27 trials is the only prospective dataset that can assist radiotherapy decisions in the neoadjuvant setting. Although the results of this analysis should be validated with modern studies (i.e., proper anti-Her-2 and hormonal treatment), selected patients (cT1–2, cN1, and >40 years old) with pathological complete response (pCR) (ypT0, ypTis, ypN0) and non-triple-negative histology after neoadjuvant chemotherapy could possibly be followed without postmastectomy radiotherapy (PMRT) and without regional irradiation in a breast-conserving setting.


Neoadjuvant chemotherapy Preoperative chemotherapy Postmastectomy radiotherapy (PMRT) Lymphatic radiotherapy Radiotherapy (RT) 


  1. 1.
    Hoffman KE, Mittendorf EA, Buchholz TA. Optimizing radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol. 2012;13(6):e270–6.CrossRefGoogle Scholar
  2. 2.
    Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;2:CD005002.Google Scholar
  3. 3.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.CrossRefGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast Cancer, Version 1; 2018.Google Scholar
  5. 5.
    Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Minckwitz G, Mamounas E, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105(5):321–33.CrossRefGoogle Scholar
  6. 6.
    Park SH, Kim MJ, Park BW, Moon HJ, Kwak JY, Kim EK. Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer. Ann Surg Oncol. 2011;18(3):738–44.CrossRefGoogle Scholar
  7. 7.
    Oh JL, Nguyen G, Whitman GJ, Hunt KK, Yu TK, Woodward WA, et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007;110(11):2420–7.CrossRefGoogle Scholar
  8. 8.
    Mamounas EP, Anderson SJ, Dignam JJ, James JD, Harry DB, Thomas BJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.CrossRefGoogle Scholar
  9. 9.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials. Lancet Oncol. 2018;19(1):27–39.CrossRefGoogle Scholar
  10. 10.
    Fowble BL, Einck JP, Kim DN, McCloskey S, Mayadev J, Yashar C, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II–III breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):494–503.CrossRefGoogle Scholar
  11. 11.
    McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1004–9.CrossRefGoogle Scholar
  12. 12.
    Settle S, Gonzalez-Angulo AM, Buchholz TA, Woodward WA, Yu TK, Oh JL, et al. Locoregional outcomes and radiotherapy response in patients with triple negative breast cancer (abstract). Int J Radiat Oncol Biol Phys. 2009;75:S9–10.CrossRefGoogle Scholar
  13. 13.
    Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):138–45.CrossRefGoogle Scholar
  14. 14.
    Le Scodan R, Selz J, Stevens D, Bollet MA, de la Lande B, Daveau C, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–7.CrossRefGoogle Scholar
  15. 15.
    Buchholz TA, Katz A, Strom EA. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:880–8.CrossRefGoogle Scholar
  16. 16.
    Garg AK, Oh JL, Oswald MJ, Huang E, Strom EA, Perkins GH, et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II–III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1478–83.CrossRefGoogle Scholar
  17. 17.
    Shim SJ, Park W, Huh SJ, Choi SJ, Shin DH, Lee KH, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.CrossRefGoogle Scholar
  18. 18.
    Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20(1):17–23.CrossRefGoogle Scholar
  19. 19.
    Daveau C, Stevens D, Brain E, Berges O, Villette S, Moisson P, et al. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys. 2010;78(2):337–42.CrossRefGoogle Scholar
  20. 20.
    Whelan T, Olivotto IA, Ackerman I. NCICCTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011;29:779s. abstr LBA1003.Google Scholar
  21. 21.
    Poortmans P, Struikmans H, Kirkove C, Budach V, Matuschek C. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC radiation oncology and breast cancer groups phase III trial 22922/10925. Eur J Cancer. 2013;49(Suppl 3):S1.Google Scholar
  22. 22.
    Bellon JR, Wong JS, Burstein HJ. Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012;30(32):3916–20.CrossRefGoogle Scholar
  23. 23.
    Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, et al. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation. Cancer. 2013;119(1):16–25.CrossRefGoogle Scholar
  24. 24.
    White J, Mamounas E. Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol. 2014;32(6):494–5.CrossRefGoogle Scholar
  25. 25.
    Rutgers EJ, Donker M, Straver ME, Meijnen, P, Van De Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J Clin Oncol. 2013;31(15)suppl: abstract LBA1001.CrossRefGoogle Scholar
  26. 26.
    Marks LB, Prosnitz LR. Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol. 2014;32(6):491–3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Makbule Tambas
    • 1
  • Kamuran Arslan Ibis
    • 2
  • Merdan Fayda
    • 3
  1. 1.Department of Radiation OncologyUniversity of Health Sciences, Okmeydanı Training and Research HospitalIstanbulTurkey
  2. 2.Istanbul Medical Faculty, Department of Radiation Oncology, Istanbul University, Institute of OncologyIstanbulTurkey
  3. 3.Istinye University, Faculty of Medicine, Department of Radiation OncologyIstanbulTurkey

Personalised recommendations